Effect of Nifedipine on Serum Lipoprotein Metabolism in Patients with Essential Hypertension

  • K. Arakawa
  • J. Sasaki
Conference paper

Abstract

Nifedipine is a calcium channel blocker that has been widely used for the treatment of hypertension (Olivari et al. 1979) and coronary artery disease (Henry 1980; Hugenholtz et al. 1981). Some antihypertensive agents have been shown to influence lipoprotein concentrations (Weidmann et al. 1985). Although some controversial data have been reported, prolonged use of chlorothiazide increases serum total cholesterol and serum triglyceride levels (Weidmann et al. 1985). β-Blockers increase triglyceride and decrease highdensity lipoprotein cholesterol (HDL-C) levels (Weidmann et al. 1985). On the other hand, α1-blockers decrease total cholesterol and triglyceride levels and increase HDL-C and the ratio of HDL to low-density liproprotein (Weidmann et al. 1985). However, the effect of calcium channel blockers on lipoprotein metabolism is unclear. Several studies showed no significant change in total cholesterol, triglyceride, and HDL-C with nifedipine (Pasanisi et al. 1986; Vessby et al. 1983; Weidmann et al.,1985) and verapamil (Faergeman et al. 1982; Lewis 1986; Walldius 1982) whereas others reported increased HDL-C with diltiazem (Pool et al. 1985) and nicardipine (Ishida et al. 1984).

Keywords

Cholesterol Ischemia Carbohydrate Lipase Hydrochloride 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Allain CC, Poon LS, Chan CS, Richmond W, Fu PC (1974) Enzymatic determination of total serum cholesterol. Clin Chem 20: 470 - 475PubMedGoogle Scholar
  2. CastelliWP, Doyle JT, Gordon T. (1977) HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study. Circulation 55: 767–772Google Scholar
  3. Eggstein M, Kreutz FH (1966) Eine neue Bestimmung der Neutralfette im Blutserum und Gewebe. I. Mitt. Prinzip, Durchfuhrung und Besprechung der Methode. Klin Wochenschr 44: 262–267Google Scholar
  4. Etingin OR, Hajjar DP (1984) Nifedipine reduces cholesterol accumulation in lipid-laden arterial smooth muscle cells. Circulation 70 [Suppl]: 11–138Google Scholar
  5. Faergeman O, Meinerts H, Hansen F (1982) Serum lipoproteins after treatment with verapamil for 6 months. Acta Med Scand 681 [Suppl]: 49–51Google Scholar
  6. Gofman JW, Young W, Tandy R (1966) Ischemic heart disease, atherosclerosis and longevity. Circulation 34: 679–697PubMedGoogle Scholar
  7. Havel RJ, Edger HA, Bragdon JH (1955) The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34: 1345–1353PubMedCrossRefGoogle Scholar
  8. Henry PD (1980) Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem. Am J Cardiol 46: 1047–1058PubMedCrossRefGoogle Scholar
  9. Henry PD, Bentley KI (1981) Suppression of atherogenesis in cholesterol-fed rabbit treatedwith nifedipine. J Clin Invest 68: 1366–1369PubMedCrossRefGoogle Scholar
  10. Hugenholtz PG, Michels HR, Serruys PW, Brower PW (1981) Nifedipine in the treatment of unstable angina, coronary spasm and myocardial ischemia. Am J Cardiol 47: 163–173PubMedCrossRefGoogle Scholar
  11. Ishida N, Matsuo R, Migita T, Tanaka Y, Fujimoto T, Baba Y, Inoue T, Satoh H, Satoh Y, Tohno T (1984) Effects of nicardipine HC1 on serum lipids and blood pressure. J Jpn Atherosclerosis Soc 12: 833–838 (with English abstr)Google Scholar
  12. Lewis GRJ (1986) Long-term results with verapamil in essential hypertension and its influence on serum lipids. Am J Cardiol 57: 35D–38DPubMedCrossRefGoogle Scholar
  13. Ohata I, Sakamoto N, Nagano K, Maeno H (1984) Low density lipoprotein-lowering and high density lipoproteinelevating effects of nicardipine in rats. Biochem Pharmacol 33: 2199–2205PubMedCrossRefGoogle Scholar
  14. Olivari MJ, Bartorelli C, Polese A, Fiorentini C, Moruzzi P, Guazzi MD (1979) Treatment of hypertension with nifedipine, a calcium antagonistic agent. Circulation 59: 1059–1062Google Scholar
  15. Pasanisi F, Ferrara AL, Lovine C, Mancini M (1986) Effects of nifedipine on insulin secretion and plasma lipids in hypertensive patients. Curr Ther Res Clin Exp 39: 894–899Google Scholar
  16. Pool PE, Seagren SC, Sable AF (1985) Effects of diltiazem on serum lipids, exercise performance and blood pressure: randomized, double-blind, placebo-controlled evaluation for systemic hypertension. Am J Cardiol 56: 86H–91HPubMedCrossRefGoogle Scholar
  17. Rhoads, GG, Gulbrandsen CL, Kagan A (1976) Serum lipoproteins and coronary heart disease in a population study of Hawaii Japanese men. N Engl J Med 294: 293–298PubMedCrossRefGoogle Scholar
  18. Stender S, Stender I, Nordestgaard B, Kjeldsen K (1984) No effect of nifedipine on atherogenesis in cholesterol-fed rabbit. Arteriosclerosis 4: 389–394PubMedCrossRefGoogle Scholar
  19. Taskinen MR, Nikkila E (1981) High density lipoprotein subfractions in relation to lipoprotein lipase activety of tissues in man - evidence for reciprocal regulation of HDL2 and HDL3 levels by lipoprotein lipase. Clin Chim Acta 112: 325–332PubMedCrossRefGoogle Scholar
  20. Vessby B, Abelin J, Finnson M, Hellsing K, Lithell H (1983) Effects of nifedipine treatment on carbohydrate and lipoprotein metabolism. Curr Ther Res Clin Exp 33: 1075–1080Google Scholar
  21. Walldius G (1982) Effect of verapamil on serum lipoproteins in patients with angina pectoris. Acta Med Scand 681 [Suppl]: 43–48Google Scholar
  22. Weidmann P. Uehlinger DE, Gerber A (1985) Antihypertensive treatment of serum lipoproteins. J Hypertens 3: 297–306PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • K. Arakawa
    • 1
  • J. Sasaki
    • 1
  1. 1.Department of Internal MedicineFukuoka University HospitalFukuokaJapan

Personalised recommendations